Data/hora: 08/06/2024 06:21:21

Provedor de dados: 	Brazilian Journal of Infectious Diseases	
País: 	Brazil	
Título: 	A randomized, comparative study of dual therapy (doxycycline–rifampin) versus triple therapy (doxycycline–rifampin–levofloxacin) for treating acute/subacute brucellosis	
Autores: 	Hasanain,Ahmad; Mahdy,Reem; Mohamed,Asmaa; Ali,Mostafa.	
Data: 	2016-06-01	
Ano: 	2016	
Palavras-chave: 	Brucellosis; Doxycycline; Rifampin; Levofloxacin.	
Resumo: 	Abstract  Aim The aim of this study was to compare both the efficacy and safety profile of the WHO-recommended, dual therapy (doxycycline–rifampin) to a quinolone-based, triple therapy (doxycycline–rifampin–levofloxacin) for treating acute/subacute brucellosis.  Patients and methods We studied 107 consecutive, naïve patients with acute/subacute brucellosis admitted to Assiut University Hospital. Patients were randomly allocated to receive the dual therapy of doxycycline–rifampin (group-A) or to receive the triple therapy of doxycycline–rifampin–levofloxacin (group-B). Acute/subacute brucellosis was diagnosed based on the presence of: (1) contact with animals or fresh animal products, (2) suggestive clinical manifestations of less than one-year duration, and (3) positive antibody titer (1:160) by standard tube agglutination test.  Results There was no significant difference between the two groups regarding their demographic data. Fever was the most frequent manifestation (96.3%). Epigastric pain was the most frequent adverse effect of treatment (12.1%). Group-A patients had a significantly higher relapse rate compared to group-B patients (22.6% versus 9.3%, p-value = 0.01). The rate of treatment adverse effects was higher among group-B patients, although not reaching statistical significance (20.4% versus 11.3%, p-value = 0.059).  Conclusions Adding levofloxacin to the dual therapy for acute/subacute brucellosis (doxycycline–rifampin) may increase its efficacy in terms of lowering the relapse rate of the disease. Further, larger scale studies are needed before considering modifying the standard, dual therapy for brucellosis.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702016000300005	
Editor: 	Brazilian Society of Infectious Diseases	
Relação: 	10.1016/j.bjid.2016.02.004	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Infectious Diseases  v.20 n.3 2016	
Fonte: 	info:eu-repo/semantics/openAccess